Our results highlight an association between the use of newer biologic agents (TCZ, RTX and GOL) and the development of non-infectious parenchymal lung disease in patients with RA. Post-marketing surveillance and biologic registries will be critical for detecting further cases of ILD and improving our understanding of the pathophysiology of this process.
As the use of these drugs increases, clinicians must remain vigilant for potential pulmonary complications and exercise caution in prescribing biologic therapies, particularly to rheumatological patients with pre-existing ILD.
2011-11-24
Eng.
Rheumatology (Oxford, England)
Addenbrooke's Hospital, CUHNHSFT, Cambridge CB2 2QQ, UK.
Rheumatology (Oxford). 2011 Dec;50(12):2297-305
© Galenicom 1999-2013